News

Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...
CDMOs gear up for peptide boom amid rising demand for weight-loss drugs
With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...
I'm a bariatric surgeon. Here's how to weigh GLP-1 or surgery
More than 40% of Americans are obese, according to the Centers for Disease Control and Prevention (CDC). And the epidemic isn ...
Ozempic and Wegovy may cut dementia risk by 45% and manage diabetes, study finds
A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street.However, the company ...
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Key Points Analyst expectations are far above the prices you'd need to pay now to own a couple of biotechnology stocks.Compass Pathways is developing psilocybin as a treatment for depression.Viking ...
Hollywood’s ‘fat funny friend’ trope is dying – here’s why that might not be a good thing
In a culture where thinness is still the price of admission, choice becomes murky. Representation becomes hollow when those who once stood outside the norm quietly conform – not necessarily because ...
Novo Nordisk Has So Much Room To Go
Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.